RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a randomized, double blind placebo controlled one-site proof-of-concept study in subjects with erosive osteoarthritis (OA) of interphalangeal (IP) finger joints. A total of 100 subjects will be enrolled into the study: 48 weeks placebo controlled double-blind phase with denosumab 60mg every 12 weeks, followed by a 48-week open-label phase in which all subjects will receive denosumab.
Epistemonikos ID: 5b25747f1bd458be247db3fb1fb6d0ebd168f9e8
First added on: May 13, 2024